Literature DB >> 31222741

The novel non-immunological role and underlying mechanisms of B7-H3 in tumorigenesis.

Xiangqi Zhou1,2, Shuhui Ouyang2, Jianjun Li3, Xin Huang4,5, Xiaohong Ai1, Yixin Zeng6, Yuncheng Lv2, Manbo Cai1.   

Abstract

B7 homolog 3 (B7-H3) has been proven to be involved in tumorigenesis. An elucidation of its role and underlying mechanisms is essential to an understanding of tumorigenesis and the development of effective clinical applications. B7-H3 is abnormally overexpressed in many types of cancer and is generally associated with a poor clinical prognosis. B7-H3 inhibits the initiation of the "caspase cascade" by the Janus kinase/signal transducers and activators of transcription pathway to resist tumor cell apoptosis. B7-H3 accelerates malignant proliferation by attacking the checkpoint mechanism of the tumor cell cycle through the phosphatidylinositol 3-kinase and protein kinase B pathway. B7-H3 reprograms the metabolism of glucose and lipids and transforms the metabolic flux of tumor cells to promote tumorigenesis. B7-H3 induces abnormal angiogenesis by recruiting vascular endothelial growth factor and matrix metalloproteinase to tumor lesions. B7-H3 strongly promotes tumorigenesis through antiapoptotic, pro-proliferation, metabolism reprogramming, and pro-angiogenesis.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  B7-H3; antiapoptotic; metabolism reprogramming; pro-angiogenesis.; pro-proliferation

Mesh:

Substances:

Year:  2019        PMID: 31222741     DOI: 10.1002/jcp.28936

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

Review 1.  Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.

Authors:  Chuan Liu; Guangwei Zhang; Kanghui Xiang; Yohan Kim; Roxane R Lavoie; Fabrice Lucien; Ti Wen
Journal:  Cancer Immunol Immunother       Date:  2021-11-05       Impact factor: 6.968

Review 2.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

3.  Comparison of the Clinicopathologic Features and T-Cell Infiltration of B7-H3 and B7-H4 Expression in Triple-negative Breast Cancer Subtypes.

Authors:  Nah Ihm Kim; Min Ho Park; NamKi Cho; Ji Shin Lee
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-04-01

4.  HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas.

Authors:  Hui Huang; Zhengyuan Huo; Jiantong Jiao; Wei Ji; Jin Huang; Zheng Bian; Bin Xu; Junfei Shao; Jun Sun
Journal:  Cancer Cell Int       Date:  2022-04-29       Impact factor: 6.429

5.  Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.

Authors:  Adrianna A Mendes; Jiayun Lu; Harsimar B Kaur; Siqun L Zheng; Jianfeng Xu; Jessica Hicks; Adam B Weiner; Edward M Schaeffer; Ashley E Ross; Steven P Balk; Mary-Ellen Taplin; Nathan A Lack; Emirhan Tekoglu; Janielle P Maynard; Angelo M De Marzo; Emmanuel S Antonarakis; Karen S Sfanos; Corinne E Joshu; Eugene Shenderov; Tamara L Lotan
Journal:  Cancer       Date:  2022-03-25       Impact factor: 6.921

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.